Where science and business join for impact
The American Society of Hematology (ASH) is the world's largest professional society concerned with the causes and treatments of blood disorders. The Society provides multiple opportunities for corporations, foundations, and other organizations to engage with leading hematologists around the world and demonstrate support that advances the field of hematology. There are a variety of opportunities for industry to support the Society's educational programs and annual meeting materials and services. As a benefit for supporting ASH initiatives, priority points are awarded. These points determine your ranking and placement on the exhibit floor at future ASH annual meetings.
Business Development, Your Innovation Partners
Business Development works to foster meaningful relationships with all those who make curing blood-based disorders their priority. As the conduit for these partnerships, our team amplifies the specific strengths each interest group offers to create opportunities for engagement that highlights each stakeholder.
Just as blood is integral to all bodily functions, ASH is integral to facilitating dynamic progress in the fight to treat and eventually cure all hematologic disorders.
-
ASH Annual Meeting and Exposition
The premier event in malignant and classical hematology, the ASH annual meeting highlights the highest-caliber science and the most important areas of clinical progress in hematology.
-
Award Support Opportunities
ASH provides many awards and programs to support hematologists in all stages of their careers and to honor those who have helped to advance the field of hematology.
-
Corporate Friends
The Corporate Friends Program is an opportunity for true partnership and open dialogue with the American Society of Hematology and offers an exclusive opportunity to form strategic connections while fostering excellence within the field. The program offers pioneering companies an opportunity to invest in the field of hematology on an annual basis.
-
Health Equity Collective
The Health Equity Collective is a cooperative enterprise of support opportunity areas for organizations seeking to help stop the trajectory and minimize the impact of health care inequality.
Thank you to our Corporate Friends for fostering excellence in the hematology space:
Premier Circle
 |
Partner Spotlight: “We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.” |
 |
Partner Spotlight: "Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Our purpose is to reimagine medicine to improve and extend people’s lives. Our vision is to become the most valued and trusted medicines company in the world. Our strategy is to deliver high value medicine that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches." |
 |
Partner Spotlight: "At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in hematology, precision medicine, and more." |
 |
Partner Spotlight: " Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, nearly all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases." |
Partner Circle
Advocate Circle
Insider Circle
